Особенности патогенеза, клинические проявления, профилактика и лечение мукозитов у онкологических больных

Автор: Саржевский В.О., Смирнова Е.Г.

Журнал: Вестник Национального медико-хирургического центра им. Н.И. Пирогова @vestnik-pirogov-center

Статья в выпуске: 3 т.7, 2012 года.

Бесплатный доступ

Представлены современные данные о мукозитах, наиболее часто развивающихся осложнениях химиотерапии у больных, страдающих онкологическими заболеваниями. Претерпевшие в последнее десятилетие изменения представлений о патогенезе данного осложнения, подходах к оценке тяжести поражений слизистой оболочки желудочно-кишечного тракта, профилактике и лечении мукозитов могут быть интересны онкологам, гематологам и врачам других специальностей, принимающих участие в лечении онкологических пациентов.

Онкология, мукозит, химиотерапия, лучевая терапия

Короткий адрес: https://sciup.org/140188087

IDR: 140188087

Список литературы Особенности патогенеза, клинические проявления, профилактика и лечение мукозитов у онкологических больных

Andrieu-Abadie N. Sphingomyelin hydrolysis during apoptosis/Andrieu-Abadie N, Levade T.//BiophysActa 2002; 1585: 126-134.
Barasch A. Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis./Barasch A, Elad S, Altman A et al.//Support Care Cancer Jun; 2006 14(6): 528-532.
Bellm LA. Patient reports of complications of bone marrow transplantation./Bellm LA, Epstein JB, Rose-Ped A et al.//Support Care Cancer 2000; 8: 33-39.
Brown CG. Clinical consequences of oral mucositis./Brown CG, Wingard J.//SeminOncolNurs. 2004 Feb; 20(1):16-21.
Bultzingslowen I. Growth factors and cytokines in the prevention and treatment of oral and gastrointestinal mucositis./Bultzingslowen I, Brennan MT, Spijkervet FK, et al.//Support Care Cancer Jun; 2006 14 (6): 519-527.
Cheng KK. Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients./Cheng KK, Molassiotis A, Chang AM et al.//Eur J Cancer Nov; 2001 37(16): 2056-2063.
Elting LS. The burdens of Cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis./Elting LS, Cooksley C, Chambers M, et al.//Cancer 2003; 98: 1531-1539.
Hagiwara S. Altered gut bacterial flora and organic acids in feces of patients undergoing autologous stem cell transplantation with quinolone-based antibacterial prophylaxis./Hagiwara S, Hagiwara S, Asahara T et al.//GanTo Kagaku Ryoho. 2010 Jun; 37(6): 1075-9.
Henke M. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial./Henke M, Alfonsi M, Foa P et al.//JClin0ncol.2011 Jul 10; 29(20): 2815-20. Epub 2011 Jun 13.
Keefe DM. Updated clinical practice guidelines for the prevention and treatment of mucositis./Keefe DM, Schubert MM, Elting LS, et al.//Cancer Mar 1; 2007 109(5): 820-831.
Meropol NJ. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant./Meropol NJ, Somer RA, Gutheil J et al.//JClin0ncol.2003 Apr 15; 21(8): 1452-8.
Migliorati CA. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis./Migliorati CA, Oberle-Edwards L, Schubert M.//Support Care Cancer Jun; 2006 14(6): 533-540.
Paris F. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice./Paris F, Fuks Z, Kang A, et al.//Science 2001; 293: 293-297.
Peterson D.E. Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines./Peterson D.E., Bensadoun R-J, Roila F.//Annals of Oncology 21: 261-265, 2010.
Ralf-Peter Vonberg. Clostridium difficile: a challenge for hospitals. European Center for Disease Prevention and Control. Institute for Medical Microbiology and Hospital Epidemiology: IHE. Retrieved 27 July 2009.
Silverman S. Jr. Diagnosis and management of oral mucositis. О Support Oncol 2007; 5 (suppl 1): 13-21.
Sonis ST. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients./Sonis ST, Elting LS, Keefe D. et al.//Cancer 2004; 1995-2025.
Sonis ST. The biologic role for nuclear factor-kappa B in disease and its potentional involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 2002; 13: 380-389.
Sonis ST. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis./Sonis ST, O’Donnell KE, Popat R, et al.//Oral Oncol 2004; 40: 170-176.
Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncology 2007; 5: 3-11.
Spielberger R. Palifermin for oral mucositis after intensive therapy for hematologic cancers./Spielberger R, Stiff P, Bensinger W, et al.//N Engl J Med Dec 16; 2004 351(25): 2590-2598.
Toor AA. Infections during mobilizing chemotherapy and following autologous stem cell transplantation./Toor AA, van Burik JA, Weisdorf DJ.//BoneMarrowTransplant. 2001 Dec; 28(12): 1129-34.
Ulrich CM. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolatereductase C677T polymorphism./Ulrich CM, Yasui Y, Storb R, et al.//Blood 2001; 98: 231-234.
Vadhan-Raj S. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial./Vadhan-Raj S, Trent J, Patel S et al.//Ann Intern Med. 2010 Sep 21; 153(6): 358-67.
Wearing HJ. Keratinocyte growth factor signaling: a mathematical model of dermal-epidermal interaction in epidermal wound healing./Wearing HJ, Sherratt JA.//Math Biosci 2000; 165: 41-62.

Еще

Статья обзорная